Japanese encephalitis vaccine is a vaccine that protects against Japanese encephalitis. The vaccines are more than 90% effective. How long this protection lasts is not clear but its effectiveness appears to decrease over time. Doses are given either by injection into a muscle or just under the skin.
It is recommended as part of routine immunizations in countries where the disease is a problem. One or two doses are given depending on the version of the vaccine. Extra doses are not typically needed in areas where the disease is common. In those with HIV/AIDS or those who are pregnant an inactivated vaccine should be used. Immunization of travellers who plan to spend time outdoors in areas where the disease is common is recommended.

The global Japanese Encephalitis (JE) Vaccine market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Japanese Encephalitis (JE) Vaccine volume and value at global level, regional level and company level. From a global perspective, this report represents overall Japanese Encephalitis (JE) Vaccine market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Japanese Encephalitis (JE) Vaccine in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Japanese Encephalitis (JE) Vaccine manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
GSK
Sanofi
Chengdu institute of biologica
Wuhan Institute of Biological
Lanzhou Institute of Biological
Beijing Taitan
Valneva
Bharat Biotech
Biological E. Limited
Liaoning Chengda

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Inactivated Vaccine
Live Attenuated Vaccine

Segment by Application
Public
Private